Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine
August 14, 2024 07:07 ET
|
Panavance Therapeutics Inc.
Misetionamide demonstrated significant single agent activity and synergy with either PARP inhibitors (PARPi) or bevacizumab in ovarian cancer preclinical studiesProfound effects on tumor metabolism,...
Worldwide Filgrastim Industry to 2027 - An Increase in the Aging Population is Driving Growth
January 21, 2022 04:29 ET
|
Research and Markets
Dublin, Jan. 21, 2022 (GLOBE NEWSWIRE) -- The "Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027"...